We are thrilled to lead TRexBio's $84M Series B alongside a wonderful group of co-investors in SV Health Investors, Eli Lilly and Company, Pfizer, Avego, Agent Capital, Alexandria Real Estate Equities, Inc., Polaris Partners, and Johnson & Johnson. TRexBio has decoded human tissue samples to build a pipeline of novel programs related to regulatory T cells and immune homeostasis, and this financing will support pushing the lead program, TRB-061, a novel TNFR2 agonist for the treatment of inflammatory diseases, through early clinical proof of concept. We believe that enabling immune homeostasis could represent the next great pillar for treating patients with immune-mediated diseases, and we are excited to support Johnston Erwin, Laura Berner, Melanie Kleinschek, and the entire team at TRexBio as they continue to advance the field! https://lnkd.in/dANECpdX
Delos Capital
风险投资与私募股权管理人
We empower life sciences leaders to turn bold ideas into medical breakthroughs.
关于我们
Delos Capital is a life sciences investment firm. Our team draws upon diverse skills and a global network?to support ground-breaking innovations that will improve lives around the world. Our rigorous investment process combines a deep understanding of biology, unmet needs in medicine, and building high-performing companies to bring medical breakthroughs to patients.
- 网站
-
https://www.deloscapital.com
Delos Capital 的外部链接
- 所属行业
- 风险投资与私募股权管理人
- 规模
- 11-50 人
- 总部
- Boston
- 类型
- 私人持股
- 创立
- 2014
- 领域
- Healthcare、Lifesciences、Private Equity、Venture Capital和biotechnology
地点
-
主要
获取路线
US，Boston
Delos Capital 员工
动态
-
Congratulations to the Alpha-9 Oncology team led by David Hirsch on their $175 million Series C financing to advance multiple radiopharmaceutical cancers into clinical studies! We are proud investors and believe this pipeline of medicines is going to make a lasting impact for many people living with cancer. Thanks to Ascenta Capital and Lightspeed for leading this financing, as well as the other fantastic new and existing investors in this syndicate General Catalyst, RA Capital Management, Janus Henderson Investors, a16z Bio + Health, Digitalis Ventures, Lumira Ventures, abrdn, Frazier Life Sciences, Longitude Capital, Nextech Invest, BVF PARTNERS, L.P, and Samsara BioCapital.
Today Alpha-9 Oncology Inc. announces the closing of oversubscribed $175 million Series C financing to advance its diverse clinical pipeline of #radiopharmaceuticals for effective #cancer treatments. The Financing was led by Lightspeed Venture Partners and Ascenta Capital. Learn more: https://lnkd.in/gG3qqDgg
-
-
Congratulations to our portfolio company Eccogene and its partner AstraZeneca for the speedy advancement of ECC5004/AZD5004 into two Ph2b trials for obese and diabetic patients!
We are pleased to announce that our partner AstraZeneca dosed the first patients in the two Phase 2 trials of ECC5004/AZD5004 for the treatment of obesity and type diabetes. For more information, click here:?https://lnkd.in/d4SW3RmM
-
-
Exciting news from Rgenta Therapeutics Inc. on it Phase 1 study of the novel SMx RGT-61159 for treatment of ACC and RCC. We look forward to more clinical data in demonstrating its therapeutic potential.
We are excited to announce that we have dosed the first cohort of patients in our first-in-human Phase 1a/b clinical trial to evaluate oral small molecule drug candidate, RGT-61159 in patients with adenoid cystic carcinoma (ACC) or colorectal cancer (CRC).?? ? RGT-61159 is designed to selectively target MYB RNA and inhibit oncogenic MYB protein production whose aberrant expression has been demonstrated in multiple forms of human cancer including ACC, CRC, acute myeloid leukemias (AML), T-cell acute lymphoblastic leukemias (T-ALL), small cell lung cancer (SCLC) and breast cancer.??? ? Learn more about RGT-61159 here: https://lnkd.in/gYBpyvrm
-
-
Delos Capital 转发了
PRESS RELEASE: Tanvex CDMO is excited to share news about our alliance with Bora Pharmaceuticals. Combining Tanvex’s biosimilar development expertise and U.S. FDA-licensed commercial-scale facility in San Diego, California, with Bora’s extensive global CDMO capabilities, the alliance aims to provide comprehensive solutions to biologics CDMO customers around the world. https://lnkd.in/g2YRW_-j #PressRelease #CDMO #Pharma #biotech #Biologics #Biosimilars #Innovation #Biotech #Partnerships #tanvexCDMO #pharma #pharmaindustry #pharmaceutical #pharmaceuticalindustry #cdmo #contractmanufacturing
Tanvex BioPharma Forging Strategic Alliance With Bora Pharmaceuticals
newswire.com
-
Congratulations to the outstanding team at Zenas BioPharma ($ZBIO) for executing on a strong Nasdaq IPO that will finance multiple clinical studies to prove the ability of #obexelimab and other pipeline programs to meaningfully improve the lives of many patients with #autoimmune diseases. We are proud to have co-led the series C earlier this year and our conviction in the ability of the Zenas team to develop and commercialize high-impact medicines has never been stronger with this additional >$200M from a deep syndicate of top public investors. Onward! cc Jennifer Fox Lonnie Moulder Joe Farmer Orlando Oliveira SR One Capital Management New Enterprise Associates (NEA) Norwest Venture Partners Enavate Sciences Agent Capital Longitude Capital Fairmount Funds Management LLC
We are thrilled to share the news of our IPO and to be Nasdaq-listed as ZBIO! This financing allows Zenas Bio to continue to advance our mission to become a global leader in the development and commercialization of immunology-based therapies so that patients with autoimmune diseases can reimagine life. Thank you to everyone who has supported us! ? #IPO #Nasdaqlisted #ZenasBio #immunology #autoimmunediseases
-
-
Congratulations to our portfolio company Imperative Care for a successful financing to fuel its commercialization efforts and bring best-in-class care to more patients!
Today we announced the initial close of our successful Series E financing and the appointment of Shacey Petrovic to Vice Chair of our Board of Directors. Read the press release for more:?https://bit.ly/46kDvg0 ? Together, these milestones fuel Imperative Care’s efforts to rapidly expand solutions to stroke and other devastating vascular diseases and position us for long term scale and success.
-
Big congratulations to the Tulavi Therapeutics team led by Josh Vose for their FDA clearance of allay? Nerve Cap! Delos was one of Tulavi's seed investors and our managing partner Henry Chen is a co-founder of the company, and so we are quite eager and proud to see Tulavi improve outcomes for many patients as allay? Nerve Cap becomes a commercial product. We also believe Tulavi will continue to advance peripheral nerve care with other innovative programs!
What a special moment in time. Last week the Tulavi Therapeutics team received FDA clearance to market for the groundbreaking allay? Nerve Cap! allay? is nothing short of a major advancement. As a De Novo, it is entirely unique: the first and only fully resorbable, sutureless, in situ forming hydrogel device designed to conform to and protect transected peripheral nerves, block axonal escape, and reduce the risk of neuroma formation. Words don't do justice to how proud I am of this group and our mission. This milestone is a testament to the vision, dedication, and tenacity of Corinne Bright, Fred Khosravi, Amar Sawhney, and Henry Chen who chose to dramatically advance the standard of care; Yong Ren and Sophia Campbell who put in so many long days and nights to shepherd allay? to this moment; our Board and the outstanding Tulavi team who will take us into clinical care (Patrick Chiu, John Treboutat, Adam Vojta, Jared Neveu, Ken Xavier, Shruti Pathak, Joe Oliver, Paul Lonergan, MBA, Nicole Lane) On a personal level, completion of this De Novo marks the dawn of a new era in the field where I began my career so long ago at SaluMedica with Lani Paxton MD PhD and David Ku MD PhD of The Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. Without their vision and mentorship would I have ever understood what this field could become and what Tulavi's portfolio of upcoming products has the potential to deliver. I am still so grateful for that experience. We look forward to seeing you in the OR!
-
-
Delos Capital 转发了
We are proud to be part of this financing round, enabling the great team at Cardurion Pharmaceuticals to advance multiple clinical trials in cardiovascular diseases where patients need better treatments. Thanks to Ascenta Capital for leading the way, and the rest of this strong syndicate Bain Capital Life Sciences Fund LP, New Enterprise Associates (NEA), GV (Google Ventures), Fidelity Management And Research Company, Millenium Capital Management, Farallon Capital Management, The Invus Group, Blue Owl Capital, Digitalis Ventures
Today we announce a $260M Series B financing, which will support continued progress with our two clinical stage drug candidates and expansion of?our #cardiovasculardisease portfolio. https://cardurion.com/ #heartfailure #CVdruginnovation https://lnkd.in/ed-h3Z-s
-
-
We are proud to be part of this financing round, enabling the great team at Cardurion Pharmaceuticals to advance multiple clinical trials in cardiovascular diseases where patients need better treatments. Thanks to Ascenta Capital for leading the way, and the rest of this strong syndicate Bain Capital Life Sciences Fund LP, New Enterprise Associates (NEA), GV (Google Ventures), Fidelity Management And Research Company, Millenium Capital Management, Farallon Capital Management, The Invus Group, Blue Owl Capital, Digitalis Ventures
Today we announce a $260M Series B financing, which will support continued progress with our two clinical stage drug candidates and expansion of?our #cardiovasculardisease portfolio. https://cardurion.com/ #heartfailure #CVdruginnovation https://lnkd.in/ed-h3Z-s
-